Biogen

BIIB is the ticker symbol for Biogen, a company classified under the Biotechnology industry within the broader Health Care sector.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Key metrics include a return on equity of 2.2%, a debt-to-equity ratio of 0.73.

The company reports trailing twelve-month revenue of $2.48B and net income of $319.50M.

FINOTAUR aggregates real-time and fundamental data on BIIB to help traders and investors make informed decisions. Track BIIB in your trading journal alongside other positions for a unified view of your portfolio.